Out-licensing

Molecular Diagnostics

An example of our successful out-licensing strategy in the diagnostics field are our agreements with Labco Quality Diagnostics and Diacarta to launch our non-invasive test to detect genetic material in circulating-free DNA (cfDNA) in serum and plasma of cancer patients. LABCO is the largest DX provider in Europe and has significant presence in Latin America while Diacarta will commercialize our liquid biopsy assay in the U.S.A and China.


We focus on reaching agreements with companies which have:

  • Wide distribution capabilities

  • A clear focus on new emerging technologies and novel content

  • Financial resources

Drug Development

We are actively pursuing an innovative Drug Development program focusing on first-in-class or best-in-class new chemical entities for cancer indications with high unmet needs and are open to collaboration at any stage of pre-clinical and clinical development.

For further details of out-licensing opportunities: Contact us

 




We use first and third party cookies to track your browsing habits on our website in order to provide you with better quality and security, and improve the services offered through this website. If users do not explicitly confirm that they consent to the installation of cookies but continue to browse our website, we will assume that they have agreed and we will inform them accordingly about the possibility of blocking or deleting any previously installed cookies by adjusting their browser settings. You can find out more about cookies in our "Cookie Policy".

COOKIE POLICY